Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Calcium × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Plasma cell 1 Gastrointestinal 1

Conditions

Neoplasm, Residual 1

Interventions

pembrolizumab 55 Paclitaxel 47 Gemcitabine 44 Carboplatin 41 Docetaxel 35 Pemetrexed 26 Cisplatin 26 Bevacizumab 25 Nivolumab 23 atezolizumab 19 Fluorouracil 19 Capecitabine 19 Cetuximab 17 Leucovorin 16 Irinotecan 16 Erlotinib Hydrochloride 15 Afatinib 15 Trastuzumab 13 130-nm albumin-bound paclitaxel 12 regorafenib 11 olaparib 11 trametinib 10 Sorafenib 10 Ipilimumab 10 Injections 10 Drug Therapy 10 eribulin 9 enzalutamide 9 Oxaliplatin 9 Cyclophosphamide 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡